<DOC>
	<DOCNO>NCT02479490</DOCNO>
	<brief_summary>This multicenter prospective study include patient metastatic Renal Cell Cancer ( RCC ) pre- treat VEGFR TKI eight Italian cancer center . Everolimus formulate tablet 5-10 mg strength , blister-packed aluminium foil unit 10 tablet . Prednisone dispense patient dose 5 mg twice daily ( BID ) . Everolimus dose 10 mg ( one 10 mg tablet two 5 mg tablet ) . Both drug self-administered orally , continuously Day 1 ( Visit 2 ) progression disease , unacceptable toxicity , death discontinuation reason . A treatment cycle consist 28 day .</brief_summary>
	<brief_title>PRednisone Plus EVerolimus Patients With Metastatic Renal Cell Cancer After Failure VEGFR -TKI</brief_title>
	<detailed_description>Title Phase II study oral PRednisone 5 mg bid plus EVerolimus patient metastatic renal cell cancer failure vascular endothelial growth factor receptor-tyrosine kinase inhibitor ( PREV study ) . Short Title/ Acronym PREV Protocol Code IRST189.04 Phase Phase 2 Study Design This multicenter prospective study include patient metastatic RCC pre- treat VEGFR TKI eight Italian cancer center . Study Duration 2 year recruitment 1 year follow-up Study Center ( ) multi-center : 8 center involve Objectives Primary objective : To evaluate safety tolerability prednisone 5 mg bid everolimus 10 mg/day RCC . Secondary objective : To evaluate activity clinical outcome patient . Exploratory objective : To evaluate influence prednisone trough concentration everolimus correlation incidence side effect , particular stomatitis non-infectious pneumonitis . Infiammation marker pentraxin 3 ( PTX3 ) , IL-6 , TGF-β neutrophil-lymphocyte ratio correlate clinical outcome ( ORR , PFS , OS ) . Number Subjects 42 subject Diagnosis Main Inclusion Criteria Patients mRCC fail least one VEGFR TKI . Main Inclusion Criteria : - Patients renal cell carcinoma fail least one VEGFR TKI - Patients adequate bone marrow function - Patients adequate liver function - Patients adequate renal function Diagnosis Main Inclusion Criteria ( continue ) Main exclusion criterion : - CNS disease OR patient presence history central nervous system ( CNS ) lymphoma - Patients receive chronic , systemic treatment corticosteroid another immunosuppressive agent ( except corticosteroid daily dosage equivalent prednisone ≤ 20 mg adrenal insufficiency ) . However , patient receive corticosteroid must stable dose ≥ 4 week prior first dose everolimus . Topical inhale corticosteroid permit . - Patients know hypersensitivity everolimus rapamycins ( sirolimus , temsirolimus ) excipients - Patients uncontrolled hyperlipidemia ( ≥ Grade 3 hyperlipidemia despite optimal supportive medical therapy ) - Patients active , bleed diathesis - Previous organ transplantation - Patients severe and/or uncontrolled medical condition condition could affect participation study Study Product , Dose , Route , Regimen duration administration Everolimus formulate tablet 5-10 mg strength , blister-packed aluminium foil unit 10 tablet . Prednisone dispense patient dose 5 mg twice daily ( BID ) . Everolimus dose 10 mg ( one 10 mg tablet two 5 mg tablet ) . Both drug self-administered orally , continuously Day 1 ( Visit 2 ) progression disease , unacceptable toxicity , death discontinuation reason . A treatment cycle consist 28 day . Reference therapy Not applicable Statistical Methodology This multicenter prospective study include patient metastatic RCC pre- treat VEGFR TKI eight Italian cancer center . The study analyze intent-to-treat basis . Secondary parameter analyze exploratively intent-to-treat population .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>1 . Age ≥ 18 year old 2 . Patients histopathologically confirm diagnosis renal cell carcinoma 3 . Patients renal cell carcinoma fail least one VEGFR TKI 4 . Patients adequate bone marrow function define ANC ≥ 1.5 x 109/L , Platelets ≥ 80 x 109/L , Hb &gt; 9 g/dL 5 . Patients adequate liver function define serum bilirubin ≤ 1.5 x ULN , ALT AST ≤ 2.5x ULN . Patients know liver metastasis AST ALT ≤ 5x ULN 6 . Patients adequate renal function define serum creatinine ≤ 1.5 x ULN 7 . Patients give write informed consent obtain accord local guideline 1 . CNS disease OR patient presence history central nervous system ( CNS ) lymphoma 2 . Patients receive chronic , systemic treatment corticosteroid another immunosuppressive agent ( except corticosteroid daily dosage equivalent prednisone ≤ 20 mg adrenal insufficiency ) . However , patient receive corticosteroid must stable dose ≥ 4 week prior first dose everolimus . Topical inhale corticosteroid permit . 3 . Patients know hypersensitivity everolimus rapamycins ( sirolimus , temsirolimus ) excipients 4 . Patients uncontrolled hyperlipidemia ( ≥ Grade 3 hyperlipidemia despite optimal supportive medical therapy ) 5 . Patients active , bleed diathesis 6 . Previous organ transplantation 7 . Patients severe and/or uncontrolled medical condition condition could affect participation study : unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction within 6 month start study drug , serious uncontrolled cardiac arrhythmia clinically significant cardiac disease severely impaired lung function ( spirometry DLCO 50 % normal predict value and/or Oxygen saturation 88 % less rest , room air ) uncontrolled diabetes define fast serum glucose &gt; 1.5 x ULN active ( acute chronic ) uncontrolled infections/disorders non malignant medical illness uncontrolled whose control may jeopardize treatment study therapy liver disease cirrhosis severe hepatic impairment ( ChildPugh class C ) . Note : detailed assessment Hepatitis B/C medical history risk factor must do screening patient . HBV DNA HCV RNA PCR test require screening patient positive medical history base risk factor and/or confirmation prior HBV/HCV infection . 8 . A known history HIV seropositivity 9 . Female patient pregnant breast feeding , adult reproductive potential willing use effective birth control method . If barrier contraceptive use , must continue throughout treatment sex . 10 . Patients unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>metastatic renal cancer</keyword>
	<keyword>failure VEGFR_TKI</keyword>
	<keyword>prednisone</keyword>
	<keyword>everolimus</keyword>
</DOC>